случаев эти патогены эффективно не распространялись среди людей, и болезни ограничивались очень небольшим количеством зараженных.
Комментарии
1
S. Duffy, “Why are RNA virus mutation rates so damn high?” PloS Biol., vol. 16, no. 8, p. e3000003, Aug. 2018.
2
C. A. Suttle, “Viruses in the sea,” Nature, vol. 437, no. 7057, pp. 356–361, Sep. 2005.
3
K. Wang et al., “SARS-CoV-2 invades host cells via a novel route: CD147-spike protein,” bioRxiv, p. 2020.03.14.988345, Jan. 2020.
4
X. Wang et al., “SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion,” Cell. Mol. Immunol., Apr. 2020.
5
H. Wang et al., “SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway,” Cell Res., vol. 18, no. 2, pp. 290–301, Feb. 2008.
6
M. Hoffmann et al., “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor,” Cell, vol. 181, no. 2, pp. 271–280.e8, Apr. 2020.
7
J. Shang et al., “Cell entry mechanisms of SARS-CoV-2,” Proc. Natl. Acad. Sci., vol. 117, no. 21, pp. 11727–11734, May 2020.
8
E. Braun and D. Sauter, “Furin-mediated protein processing in infectious diseases and cancer,” Clin. Transl. Immunol., vol. 8, no. 8, Jan. 2019.
9
K. Kuba, Y. Imai, and J. M. Penninger, “Multiple Functions of Angiotensin-Converting Enzyme 2 and Its Relevance in Cardiovascular Diseases,” Circ. J., vol. 77, no. 2, pp. 301–308, 2013.
10
T. Ivanova et al., “Optimization of Substrate-Analogue Furin Inhibitors,” ChemMedChem, vol. 12, no. 23, pp. 1953–1968, Dec. 2017.
11
Y. M. Bar-On, A. Flamholz, R. Phillips, and R. Milo, “SARS-CoV-2 (COVID-19) by the numbers,” Elife, vol. 9, Apr. 2020.
12
K. B. Anand, S. Karade, S. Sen, and R. M. Gupta, “SARS-CoV-2: Camazotz’s Curse,” Med. J. Armed Forces India, vol. 76, no. 2, pp. 136–141, Apr. 2020.
13
D. E. Gordon et al., “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing,” Nature, vol. 583, no. 7816, pp. 459–468, Jul. 2020.
14
Y. Zhang et al., “The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC–I,” bioRxiv, p. 2020.05.24.111823, Jan. 2020.
15
A. B. Gussow, N. Auslander, G. Faure, Y. I. Wolf, F. Zhang, and E. V. Koonin, “Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses,” Proc. Natl. Acad. Sci., vol. 117, no. 26, pp. 15193–15199, Jun. 2020.
16
M. J. Costello, R. M. May, and N. E. Stork, “Can We Name Earth’s Species Before They Go Extinct?” Science, vol. 339, no. 6118, pp. 413–416, Jan. 2013.
17
K. J. Locey and J. T. Lennon, “Scaling laws predict global microbial diversity,” Proc. Natl. Acad. Sci., vol. 113, no. 21, pp. 5970–5975, May 2016.
18
Y. Ikeda, “Feline Host Range of Canine parvovirus: Recent Emergence of New Antigenic Types in Cats,” Emerg. Infect. Dis., vol. 8, no. 4, pp. 341–346, Apr. 2002.
19
É. Leal et al., “Regional adaptations and parallel mutations in Feline panleukopenia virus strains from China revealed by nearly-full length genome analysis,” PLoS One, vol. 15, no. 1, p. e0227705, Jan. 2020.
20
K. E. Jones et al., “Global trends in emerging infectious diseases,” Nature, vol. 451, no. 7181, pp. 990–993, Feb. 2008.
21
K. E. Jones et al., “Global trends in emerging infectious diseases,” Nature, vol. 451, no. 7181, pp. 990–993, Feb. 2008.
22
W. Li, “Bats Are Natural Reservoirs of SARS-Like Coronaviruses,” Science (80-.)., vol. 310, no. 5748, pp. 676–679, Oct. 2005.
23
N. Wang et al., “Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China,” Virol. Sin., vol. 33, no. 1, pp. 104–107, Feb. 2018.
